行情

CYCCP

CYCCP

Cyclacel Pharms
NASDAQ

实时行情|Nasdaq Last Sale

6.10
-0.10
-1.64%
已收盘, 16:00 04/01 EDT
开盘
6.00
昨收
6.10
最高
6.00
最低
6.00
成交量
4
成交额
--
52周最高
6.39
52周最低
3.870
市值
201.16万
市盈率(TTM)
-12.1065
分时
5日
1月
3月
1年
5年

CYCCP 新闻

更多
  • 美联储疯狂注水欲拯救流动性危机 非农夜会否再现诡异行情?
  • 新浪财经综合 · 1小时前
  • 英航或将暂停职8成员工 全球民航业今年将损失2520亿美元
  • 新浪财经 · 1小时前
  • 美企争相贷款补充流动性 一周融资近千亿美元
  • 界面新闻 · 2小时前
  • CSI:ETF在稳定市场中的作用
  • 新浪财经综合 · 2小时前

所属板块

生物技术和医学研究
-4.52%
制药与医学研究
-2.91%

热门股票

代码
价格
涨跌幅

CYCCP 简况

Cyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. Its family of anticancer drugs that act on the cell cycle include sapacitabine, seliciclib and CYC065. Its lead candidate, sapacitabine, is an orally available nucleoside analog. A number of nucleoside drugs, such as gemcitabine and cytarabine, also known as Ara-C, both generic drugs, are in use as conventional chemotherapies. Seliciclib, its lead CDK inhibitor, is an oral inhibitor of CDK2/9 enzymes that are central to the process of cell division and cell cycle control. Its second-generation CDK inhibitor, CYC065, is an inhibitor of CDKs targeting CDK2/9 enzymes with utility in both hematological malignancies and solid tumors.
展开

微牛提供Cyclacel Pharmaceuticals Inc(NASDAQ-CYCCP)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的CYCCP股票新闻,以帮助您做出投资决策。